What is the recommended tapering schedule for mirtazapine (Remeron) 30 mg nightly?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering Schedule for Mirtazapine 30 mg

A gradual tapering of mirtazapine 30 mg is strongly recommended, with dose reductions of approximately 25% every 1-2 weeks to minimize withdrawal symptoms. 1

Recommended Tapering Schedule

Mirtazapine should be tapered gradually rather than stopped abruptly to avoid withdrawal symptoms. Based on the FDA drug label and clinical evidence, here is a specific tapering schedule:

  1. Week 1-2: Reduce from 30 mg to 22.5 mg nightly
  2. Week 3-4: Reduce to 15 mg nightly
  3. Week 5-6: Reduce to 7.5 mg nightly
  4. Week 7-8: Discontinue

This schedule follows the FDA recommendation that "dose changes should not be made in intervals of less than 1 to 2 weeks to allow sufficient time for evaluation of response to a given dose" and to "gradually reduce the dosage rather than stopping abruptly whenever possible." 1

Rationale and Evidence

The FDA drug label explicitly states that adverse reactions may occur upon discontinuation of mirtazapine and recommends gradual dose reduction rather than abrupt discontinuation 1. This is supported by case reports documenting severe withdrawal symptoms after sudden discontinuation, including recurrent panic attacks that persisted until medication was reintroduced 2.

While the FDA label doesn't specify exact tapering increments, clinical guidelines recommend a gradual reduction of approximately 25% every 1-2 weeks for antidepressants to minimize withdrawal symptoms 3. This is particularly important for mirtazapine, which has a half-life of 20-40 hours and acts on both noradrenergic and serotonergic systems 4, 5.

Monitoring During Tapering

Potential Withdrawal Symptoms to Monitor

  • Anxiety and panic attacks
  • Sleep disturbances
  • Dizziness
  • Nausea
  • Irritability
  • Tremors
  • Sweating

Management of Withdrawal Symptoms

  • If withdrawal symptoms become problematic, consider slowing the taper or temporarily returning to the previous dose before attempting a slower taper
  • Adjunctive medications may be used temporarily to manage specific withdrawal symptoms

Special Considerations

When to Consider a Slower Taper

  • Patients who have been on mirtazapine for extended periods (>6 months)
  • Previous history of antidepressant withdrawal symptoms
  • Elderly patients
  • Patients with anxiety disorders

When to Consider a More Rapid Taper

  • Medical necessity requiring prompt discontinuation
  • Severe adverse effects from the medication

Pitfalls to Avoid

  1. Abrupt discontinuation: Even after medium-length therapy (10 weeks), abrupt discontinuation can lead to withdrawal symptoms including panic attacks 2

  2. Tapering too quickly: Standard recommendations of 2-4 weeks for antidepressant tapering often show minimal benefits over abrupt discontinuation and may not be tolerated by patients 6

  3. Mistaking withdrawal for recurrence: Withdrawal symptoms can be mistaken for recurrence of the underlying condition, potentially leading to unnecessary long-term medication 6

  4. Overlooking the need for lower final doses: Research suggests tapering to doses lower than minimum therapeutic doses may be more successful in reducing withdrawal symptoms 6

By following this gradual tapering schedule and monitoring for withdrawal symptoms, the risk of adverse effects from mirtazapine discontinuation can be minimized while ensuring patient safety and comfort.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.